Basing drug reimbursement on cost-effectiveness provides too little incentives for R&D. The reason for this is that cost-effectiveness is concerned with immediate value for money. But since the price of a drug usually declines over time, the drug might well provide value for money as seen over...

It is often argued that drug companies do not wish to carry out post-approval head-to-head clinical trials, since their drugs may be revealed as being no better than existing drugs. However, we show that standard models for vertical differentiation predicts that pharmaceutical companies would in...

Objective: To decompose drug spending in Sweden between the years 1990 and 2000. This paper updates a previous study, which looked at the period 1990-1995, by providing an additional 5 years of data (1995-2000) and extending the previous analysis in a number of ways. Methods: The paper builds on...

No Abstract

Using Swedish household data from 1992, I analyze whether households disproportionately burdened by an increased carbon dioxide tax can be compensated by changes in other commodity taxes. This is done by searching for Dalton–improving tax reforms (DI-reforms), a method for welfare analysis...

Basing drug reimbursement on cost-effectiveness provides too little incentives for R&D. The reason for this is that cost-effectiveness is concerned with immediate value for money. But since the price of a drug usually declines over time, the drug might well provide value for money as seen over...